McKesson Corporation vs Invesco Solar ETF — how do they compare? McKesson Corporation trades at $942.78 (market cap $108.46B), while Invesco Solar ETF trades at $43.64 (market cap $894.08M). The key difference: McKesson Corporation is far larger — about 121.3× Invesco Solar ETF's market cap, and McKesson Corporation pays a 0.4% dividend while Invesco Solar ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Invesco Solar ETF for 34 Days on average.
| MCK | TAN | |
|---|---|---|
Market Cap | $108.46B | $894.08M |
Volume | 712,607 | 370,994 |
Sector | Health | Sector/Thematic |
52-Week High | $995.69 | $73.95 |
52-Week Low | $725.17 | $43.00 |
Typical Hold Time | 74 Days | 34 Days |
Enterprise Value | $115.00B | — |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $937.98, up 3.04% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent positive developments include the CVS Health partnership extension through 2032 and raised full-year guidance. Revenue growth remains robust at $359.05 billion for 2025, though net margins are thin at 1.12%.
The outlook remains positive with 81% analyst buy ratings and a $956.43 consensus target. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. Strong cash flow generation ($6.09B operating cash flow) supports the dividend and growth initiatives, while technical indicators show the stock testing resistance near $938.
TAN trades at $43.6, up 0.16% on the day, amid a bearish technical signal with moving averages and key indicators like ADX signaling sell conditions. The ETF faces headwinds from high borrowing costs impacting solar project financing, as noted in recent news. Financial ratios are unavailable, but the fund's high expense ratio of 0.7% and historical volatility are points of concern for investors.
Outlook remains cautious due to sector-specific risks like interest rate sensitivity and market saturation. Investment opportunities exist for those bullish on long-term solar adoption, but risks include policy uncertainty and cost pressures. Analyst sentiment is mixed, with some highlighting underperformance versus broader markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →